Explore terminated, suspended, and withdrawn clinical trials

Other - DLT assessment and phase 2 dose determination

Terminated: futility criteria met at interim efficacy analysis.

Administrative hold pending non-safety related changes to the study design.

Other - Pending amendment.

After reviewing available safety and efficacy data to date, Iovance concluded the study reached the required number of events for evaluation of study endpoints.

Other - study has reached accrual goal for analysis

Feasibility considerations - extended timelines to complete recruitment

End of Initial Phase of Multi-phase protocol

Sponsor decision

Other - Pending amendment.

Scheduled Interim Monitoring

End of Initial Phase of Multi-phase protocol

Other - Pending amendment for study expansion.

The study remains on hold due to a funding issue after it's been lifted by the FDA.

Suspended due to lack of drug supply: the manufacturer ceased to provide investigational drug supply.

Low accruals

PI Request

Other - Assessing accrual feasibility

In alignment with company strategic direction.

Due to loss of funding

Slow recruitment and exhaustion of available study funding.

Drug Supply Issues

PI Request

Other - Other

End of NIH funding

Revisions to eligibility/design being made prior to enrollment of first participants.

PI Request

target number of inclusion not reached

PI request

Insufficient enrollment

Bayer cancelled study 22923 due to enrollment challenges, including difficulties identifying eligible patients, participation requirements, and site burden. The decision was unrelated to safety and does not change Mirena's benefit-risk profile.

the study was closed early due to competing trials

Funding withdrawn by sponsor.

Sponsor decision to close study due to third-party administrative error preventing analysis of trial results. There was no issue in terms of quality of the investigational product, and no safety risk to any study participant.

Sponsor Decision

The RM-202 study was terminated by the Sponsor due to redirection of the rivoceranib development plan.

The study was terminated early because recruitment of eligible children with refractory functional abdominal pain disorders was slower than anticipated, and enrollment of the planned 50 participants was not feasible within the approved study period.

Slow participant enrollment

The protocol needs to be changed before enrolling

The study was terminated based on sponsor decision unrelated to safety or efficacy. The study met the key primary and secondary endpoints, however two patients were receiving treatment at the decision point, preventing protocol-defined completion.

PI Request

Recruitment for end-points deemed not feasible.

Difficulty with accrual.

Manufacturer discontinued the production of study drugs.

No superior PFS in study group among the enrolled patients. Company R\&D strategy shifted; funding discontinued, study terminated.

The study was stopped early for business reasons (not due to changes in the benefits or risks of paltusotine).

PI departure from institution

Recruitment of chronic opioid users was substantially lower than anticipated despite extensive recruitment efforts; the study was therefore closed before reaching the planned sample size.

The study was stopped due to a lack of clear evidence of anti-tumor activity with the combination treatment in the participants treated.

The pause is for strategic business reasons to facilitate internal portfolio review. The pause is not due to any concerns with patient safety, with program benefit/risk, or with trial integrity.